Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.
 Back to Details

Connection

Rohit Dhall to Selegiline

This is a "connection" page, showing publications Rohit Dhall has written about Selegiline.

 
Connection Strength
  
 
 
0.130
  
  1. Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial. Lancet Neurol. 2015 Aug; 14(8):795-803.
    View in: PubMed
    Score: 0.130
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.